AbbVie is paying $1.4bn in cash for privately held Aliada Therapeutics and its sole clinical candidate – but if ALIA-1758 proves to be a best-in-class disease-modifying therapy for Alzheimer’s disease, that could be a bargain.
Key Takeaways
- AbbVie agreed to pay $1.4bn to acquire privately held Aliada, despite that firm having only one drug candidate in clinical development.
- AbbVie, however, called that candidate, ALIA-1758, a potential best-in-class Alzheimer’s drug that acts on pyroglutamate amyloid beta, the same target as Lilly’s recently approved Kisunla
The North Chicago biopharma announced the planned acquisition on 28 October and said the deal is expected to close during the fourth quarter. Aliada’s ALIA-1758 is a bispecific antibody that targets pyroglutamate amyloid beta (3pE-Aβ), the same target addressed by
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
